Eko Health, a company that is applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing. With participation from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, this funding round will be used to expand U.S. and global access to the company’s early disease detection platform.
This funding round builds on recent commercial and clinical milestones, including U.S. FDA clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms. And Eko’s murmur detection algorithm was clinically validated in a Massachusetts General Hospital study and found to double identification rates of structural heart murmurs versus conventional practice in primary care.
This low EF detection algorithm (developed with Mayo Clinic) was shown in an Imperial College London study to significantly enhance the identification of heart failure with reduced ejection fraction in GP clinics. And by enhancing detection capabilities, Eko’s platform significantly reduces diagnostic bottlenecks, leading to earlier interventions and improved patient outcomes.
Cardiovascular and pulmonary diseases are known to be the leading causes of death worldwide, emphasizing the critical need for early detection. Due to limited access to effective detection tools, millions of patients remain unaware of risk factors.
Eko will use the funding to deepen its presence in the U.S. and accelerate its expansion into key international markets, supported by new strategic investments from Double Point Ventures in the U.S., Singapore-based global investor EDBI (the corporate investment arm of the Singapore Economic Development Board), and LG Technology Ventures (backed by the LG Group of South Korea). With this new funding round and regulatory clearances, Eko is prepared to rapidly expand access to its AI-enabled cardiac and pulmonary disease detection platform, enabling millions of healthcare professionals to improve patient outcomes in the coming years.
KEY QUOTES:
“Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere. Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices.”
- Connor Landgraf, CEO and co-founder of Eko Health
“Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world. Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team’s dedication to saving lives by equipping hundreds of thousands—and soon millions—of clinicians worldwide with our groundbreaking early detection platform.”
- Vas Bailey, PhD, Chair of the Board at Eko Health and Partner at ARTIS Ventures
